Membranoproliferative glomerulonephritis primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Membranoproliferative glomerulonephritis}}
{{CMG}} {{AE}} {{JSS}}
{{CMG}} {{AE}} {{JSS}}



Revision as of 20:00, 6 August 2018

Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis primary prevention

CDC on Membranoproliferative glomerulonephritis primary prevention

Membranoproliferative glomerulonephritis primary prevention in the news

Blogs on Membranoproliferative glomerulonephritis primary prevention

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]

Overview

Vaccine against heptatis B and treatment of hepatitis C can be preventive for membranous glomerulopathy.

Primary Prevention

  • Effective measures for primary prevention of membranous glomerulonephritis include:[1][2]
    • Vaccine against hepatitis B can prevent hepatitis B which can lower the risk for membranous glomerulonephritis.
    • The treatment of hepatitis C can prevent the can lower the risk for membranous glomerulonephritis.


References

  1. Lai, Kar Neng; Li, Philip K.T.; Lui, Siu Fai; Au, Tak Cheong; Tam, John S.L.; Tong, Kwok Lung; Lai, Fernand Mac-Moune (1991). "Membranous Nephropathy Related to Hepatitis B Virus in Adults". New England Journal of Medicine. 324 (21): 1457–1463. doi:10.1056/NEJM199105233242103. ISSN 0028-4793.
  2. Gyapay G, Jeney A, Lapis K (1985). "Drug action and chromatin structure. I. Adriamycin binding to core particle of nucleosomes and subsequent enhanced DNA fragmentation induced by micrococcal nuclease". Neoplasma. 32 (5): 521–8. PMID 4069286.

Template:WH Template:WS